Sovatelitide (also known as sovateltide, SPI-1620, IRL-1620, and PMZ-1620) is a synthetic analog of endothelin-1 and a specific endothelin B (ETB) receptor agonist. In animal models, SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. Sovatelitide is currently investigated as an adjunct to chemotherapy in the treatment of cancer/tumors and for the treatment of central nervous system disorders in Alzheimer’s disease (AD) dementia, and for the treatment of spinal cord injury.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Sovatelitide, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.